Intraperitoneal therapy for gastric cancer peritoneal carcinomatosis

References

• Bray F, Ferlay J, and Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424
   Google Scholar
• Nakajima T, Nishi M, Kajitani T. Improvement in treatment results of gastric cancer with surgery and chemotherapy: experience of 9,700 cases in the cancer institute hospital, Tokyo. Semin Surg Oncol. 1991;7(6):365–372.
   Google Scholar
• Nashimoto A, Akazawa K, Isobe Y, et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer. 2013;16(1):1–27.
   Google Scholar
• Wang Z, Chen JQ. Imaging in assessing hepatic and peritoneal metastases of gastric cancer: a systematic review. BMC Gastroenterol. 2011;11(1):19.
   Google Scholar
• Kawanaka Y, Kitajima K, Fukushima K, et al. Added value of pretreatment (18) F-FDGPET/CT for staging of advanced gastric cancer: Comparison with contrast-enhanced MDCT. Eur J Radiol. 2016;85(5):989–995.
   Google Scholar
• Sarela AI, Lefkowitz R, Brennan MF, et al. Selection of patients with gastric adenocarcinoma for laparoscopic staging. Am J Surg. 2006;191(1):134–138.
   Google Scholar
• Miki Y, Tokunaga M, Tanizawa Y, et al. Staging laparoscopy for patients with cM0, type 4, and large type 3 gastric cancer. World J Surg. 2015;39(11):2742–2747.
   Google Scholar
• Ushimaru Y, Fujiwara Y, Kishi K, et al. Prognostic significance of basing treatment strategy on the results of photodynamic diagnosis in advanced gastric cancer. Ann Surg Oncol. 2017;24(4):983–989.
   Google Scholar
• Irino T, Sano T, Hiki N, et al. Diagnostic staging laparoscopy in gastric cancer: a prospective cohort at a cancer institute in Japan. Surg Endosc. 2018;32(1):268–275.
   Google Scholar
• Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64(1)::31–49.
   Google Scholar
• Ajani JA, D’Amico TA, Almhanna K, et al. Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016;14(10):1286–1312.
   Google Scholar
• Portilla AG, Shigeki K, Dario B, et al. The intraoperative staging systems in the management of peritoneal surface malignancy. J Surg Oncol. 2008;98(4):228–231.
   Google Scholar
• Kim DW, Jee YS, and Kim CH, et al. Group P-Gs: multicenter retrospective analysis of intraperitoneal paclitaxel and systemic chemotherapy for advanced gastric cancer with peritoneal metastasis. J Gastric Cancer. 2020;20(1):50–59.
   Google Scholar
• Rau B, Brandl A, Piso P, et al. Peritoneal metastasis in gastric cancer: results from the German database. Gastric Cancer. 2020;23(1):11–22.
   Google Scholar
• Yasufuku I, Nunobe S, Ida S, et al. Conversion therapy for peritoneal lavage cytology-positive type 4 and large type 3 gastric cancer patients selected as candidates for R0 resection by diagnostic staging laparoscopy. Gastric Cancer. 2020;23(2):319–327.
   Google Scholar
• Shitara K, Mizota A, Matsuo K, et al. Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis. Gastric Cancer. 2013;16(1):48–55.
   Google Scholar
• Osumi H, Takahari D, Chin K, et al. Modified FOLFOX6 as a first-line treatment for patients with advanced gastric cancer with massive ascites or inadequate oral intake. Onco Targets Ther. 2018;11::8301–8307.
   Google Scholar
• Shigeyasu K, Kagawa S, Uno F, et al. Multicenter phase II study of S-1 and docetaxel combination chemotherapy for advanced or recurrent gastric cancer patients with peritoneal dissemination. Cancer Chemother Pharmacol. 2013;71(4):937–943.
   Google Scholar
• Masuishi T, Nakajima TE, Yamazaki K, et al. WJOG10517G: a multicenter phase II study of mFOLFOX6 in gastric cancer patients with severe peritoneal metastases. Future Oncol. 2020;16(20):1417–1424.
   Google Scholar
• Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224–1235.
   Google Scholar
• Shitara K, Takashima A, Fujitani K, et al. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2017;2(4):277–287.
   Google Scholar
• Takashima A, Shitara K, Fujitani K, et al. Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial. Gastric Cancer. 2019;22(1):155–163.
   Google Scholar
• Coccolini F, Acocella F, Morosi L, et al. High penetration of paclitaxel in abdominal wall of rabbits after hyperthermic intraperitoneal administration of nab-paclitaxel compared to standard paclitaxel formulation. Pharm Res. 2017;34(6):1180–1186.
   Google Scholar
• Dedrick RL, Myers CE, Bungay PM, et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62(1):1–11.
   Google Scholar
• Sugarbaker PH, Mora JT, Carmignani P, et al. Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist. 2005;10(2):112–122.
   Google Scholar
• Markman M, Rowinsky E, Hakes T, et al. Phase I trial of intraperitoneal taxol: a gynecoloic oncology group study. J Clin Oncol. 1992;10(9):1485–1491.
   Google Scholar
• Ishigami H, Fujiwara Y, and Fukushima R, et al., Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: phoenix-GC trial. J Clin Oncol. 2018;36(19):1922–1929.
   Google Scholar
• Aizawa M, Ishigami H, Yabusaki H, et al. Phase II study of intraperitoneal paclitaxel plus S-1/paclitaxel for gastric cancer with positive peritoneal cytology: CY-Phoenix trial. J clin oncol. 2017;35(4_suppl):96.
   Google Scholar
• Saito S, Yamaguchi H, Ohzawa H, et al. Intraperitoneal administration of paclitaxel combined with S-1 plus oxaliplatin as induction therapy for patients with advanced gastric cancer with peritoneal metastases. Ann Surg Oncol. 2021;28(7):3863–3870.
   Google Scholar
• Kobayashi D, Ishigami H, Kanda M, et al. Phase I study of intraperitoneal administration of paclitaxel combined with S-1 plus cisplatin for gastric cancer with peritoneal metastasis. Oncology. 2020;98(1):48–52.
   Google Scholar
• Ohno S, Siddik ZH, Kido Y, et al. Thermal enhancement of drug uptake and DNA adducts as a possible mechanism for the effect of sequencing hyperthermia on cisplatin-induced cytotoxicity in L1210 cells. Cancer Chemother Pharmacol. 1994;34(4):302–306.
   Google Scholar
• van de Vaart PJ, van der Vange N, Zoetmulder FA, van Goethem AR, van Tellingen O, ten Bokkel Huinink WW, Beijnen JH, Bartelink H, Begg AC. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer. 1998;34(1):148–154.
   Google Scholar
• van Driel WJ, Koole SN, and Sikorska K. Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh I, van der Velden J, Arts HJ, Massuger L et al: hyperthermic Intraperitoneal Chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230–240.
   Google Scholar
• Quenet F, Elias D, Roca L, et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J clin oncol. 2018;36(18_suppl):LBA3503–LBA3503.
   Google Scholar
• Klaver CEL, Wisselink DD, Punt CJA, et al. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. Lancet Gastroenterol Hepatol. 2019;4(10):761–770.
   Google Scholar
• Sun J, Song Y, Wang Z, et al. Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials. BMC Cancer. 2012;12(1):526.
   Google Scholar
• Glehen O, Passot G, Villeneuve L, et al. GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study. BMC Cancer. 2014;14(1):183.
   Google Scholar
• Topal B, Demey K, Topal H, et al. Cytoreductive surgery and hyperthermic intra-operative peritoneal chemotherapy with Cisplatin for gastric peritoneal carcinomatosis monocentric phase-2 nonrandomized prospective clinical trial. BMC Cancer. 2017;17(1):771.
   Google Scholar
• Marano L, Marrelli D, Sammartino P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer with synchronous peritoneal metastases: multicenter study of ‘italian peritoneal surface malignancies oncoteam-S.I.C.O. Ann Surg Oncol. 2021;28(13):9060–9070.
   Google Scholar
• Canbay E, Mizumoto A, Ichinose M, et al. Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan. Ann Surg Oncol. 2014;21(4):1147–1152.
   Google Scholar
• Bonnot PE, Piessen G, Kepenekian V, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol. 2019;37(23):2028–2040.
   Google Scholar
• Rau B, Königsrainer HL,A, Gockel I, et al. The effect of hyperthermic intraperitoneal chemotherapy (HIPEC) upon cytoreductive surgery (CRS) in gastric cancer (GC) with synchronous peritoneal metastasis (PM): a randomized multicentre phase III trial (GASTRIPEC-I-trial). Ann Oncol. 2021;32(suppl_5):S1040–S1075.
   Google Scholar
• Newhook TE, Agnes A, Blum M, et al. Laparoscopic hyperthermic intraperitoneal chemotherapy is safe for patients with peritoneal metastases from gastric cancer and may lead to gastrectomy. Ann Surg Oncol. 2019;26(5):1394–1400.
   Google Scholar
• Badgwell B, Ikoma N, and Murphy MB, et al. A phase ii trial of cytoreduction, gastrectomy, and hyperthermic intraperitoneal perfusion with chemotherapy for patients with gastric cancer and carcinomatosis or positive cytology. Ann Surg Oncol. 2021;28(1):258–264.
   Google Scholar
• Badgwell B, Blum M, Das P, et al. Phase II trial of laparoscopic hyperthermic intraperitoneal chemoperfusion for peritoneal carcinomatosis or positive peritoneal cytology in patients with gastric adenocarcinoma. Ann Surg Oncol. 2017;24(11):3338–3344.
   Google Scholar
• Blum Murphy M, Ikoma N, Wang X, et al. Phase I trial of hyperthermic intraperitoneal chemoperfusion (hipec) with cisplatin, mitomycin, and paclitaxel in patients with gastric adenocarcinoma and associated carcinomatosis or positive cytology. Ann Surg Oncol. 2020;27(8):2806–2811.
   Google Scholar
• Koemans WJ, van der Kaaij RT, Boot H, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II). BMC Cancer. 2019;19(1):420.
   Google Scholar
• Solass W, Kerb R, Murdter T, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol. 2014;21(2):553–559.
   Google Scholar
• Solass W, Hetzel A, Nadiradze G, et al. Description of a novel approach for intraperitoneal drug delivery and the related device. Surg Endosc. 2012;26(7):1849–1855.
   Google Scholar
• Nadiradze G, Giger-Pabst U, Zieren J, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with low-dose cisplatin and doxorubicin in gastric peritoneal metastasis. J Gastrointest Surg. 2016;20(2):367–373.
   Google Scholar
• Alyami M, Bonnot PE, and Mercier F, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer. Eur J Surg Oncol. 2021;47(1):123–127.
   Google Scholar
• Struller F, Horvath P, Solass W, et al. Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C/D) in patients with gastric cancer and peritoneal metastasis: a phase II study. Ther Adv Med Oncol. 2019;11:1758835919846402.
   Google Scholar
• Di Giorgio A, Schena CA, El Halabieh MA, et al. Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): a bidirectional approach for gastric cancer peritoneal metastasis. Surg Oncol. 2020;34::270–275.
   Google Scholar
• Eveno C, Jouvin I, Pocard M. PIPAC EstoK 01: pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin (PIPAC C/D) in gastric peritoneal metastasis: a randomized and multicenter phase II study. Pleura Peritoneum. 2018;3(2):20180116.
   Google Scholar
• Oliver Goetze T, Al-Batran SE, Pabst U, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in combination with standard of care chemotherapy in primarily untreated chemo naive upper gi-adenocarcinomas with peritoneal seeding - a phase II/III trial of the AIO/CAOGI/ACO. Pleura Peritoneum. 2018;3(2):20180113.
   Google Scholar
• Yoshida K, Yamaguchi K, and Okumura N, et al. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer. 2016;19(2):329–338.
   Google Scholar
• Solaini L, Ministrini S, Bencivenga M, et al. Conversion gastrectomy for stage IV unresectable gastric cancer: a GIRCG retrospective cohort study. Gastric Cancer. 2019;22(6):1285–1293.
   Google Scholar
• Fujitani K, Yang HK, Mizusawa J, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17(3):309–318.
   Google Scholar
• Japanese CSG, Matsusaki K, Ohta K, Yoshizawa A, Gyoda Y. Novel cell-free and concentrated ascites reinfusion therapy (KM-CART) for refractory ascites associated with cancerous peritonitis: its effect and future perspectives. Int J Clin Oncol. 2011;16(4):395–400.
   Google Scholar
• Ito T, Hanafusa N. CART: cell-free and concentrated ascites reinfusion therapy against malignancy-related ascites. Transfus Apher Sci. 2017;56(5):703–707.
   Google Scholar
• Hanafusa N, Isoai A, Ishihara T, et al. Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: post-marketing surveillance results. PLoS One. 2017;12(5):e0177303.
   Google Scholar
• Yamaguchi H, Kitayama J, Emoto S, et al. Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1. Eur J Surg Oncol. 2015;41(7):875–880.
   Google Scholar
• Kurashige J, Hasegawa T, Niida A, et al. Integrated molecular profiling of human gastric cancer identifies ddr2 as a potential regulator of peritoneal dissemination. Sci Rep. 2016;6(1):22371.
   Google Scholar
• Ajani JA, Xu Y, and Huo L, et al. YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition. Gut. 2021;70(1):55–66.
   Google Scholar
• Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–209.
   Google Scholar
• Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21(5):449–456.
   Google Scholar
• Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883–892.
   Google Scholar
• Vakiani E, Janakiraman M, Shen R, et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol. 2012;30(24):2956–2962.
   Google Scholar
• Wang R, Song S, and Harada K, et al., Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut. 2020;69(1): 18–31.
   Google Scholar
• Wang R, Dang M, Harada K, et al. Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. Nat Med. 2021;27(1):141–151.
   Google Scholar
• Uchihara T, Miyake K, Yonemura A, et al. Extracellular vesicles from cancer-Associated fibroblasts containing annexin A6 induces FAK-YAP activation by stabilizing beta1 integrin, enhancing drug resistance. Cancer Res. 2020;80(16):3222–3235.
   Google Scholar